Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

endpoint was based on an intent-to-treat (ITT) analysis, which included all patients randomized in the study. However, three patients did not receive study drug but were included in the analysis as nonresponders. In the primary analysis of the combined group of patients receiving either golimumab 50 mg or 100 mg in combination with MTX, 38 percent (40 percent receiving 50 mg and 37 percent receiving 100 mg) achieved at least 50 percent improvement in signs and symptoms of RA (ACR 50) through week 24, compared with 29 percent of patients receiving placebo plus MTX (p=0.053 for the combined group, p=0.042 for 50 mg and p=0.177 for 100 mg). When the three patients who did not receive golimumab were excluded in a modified intent-to-treat (mITT) analysis, the results showed that 39 percent of patients in the combined golimumab plus MTX group (41 percent receiving 50 mg and 37 percent receiving 100 mg) achieved ACR 50, compared with 29 percent of patients receiving placebo plus MTX (p=0.049 for the combined group, p=0.038 for 50 mg and p=0.177 for 100 mg). Additionally, 62 percent of patients in the combined golimumab plus MTX group (62 percent for each dose group) achieved ACR 20, compared with 49 percent receiving placebo plus MTX (p=0.011 for the combined group and p=0.028 for each dose group).

"These data show that treatment with golimumab induces an important depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in disease activity," said Roy Fleischmann, M.D., Clinical Professor, Department of Internal Medicine at the University of Texas Southwestern Medical Center; Chief, Division of Rheumatology at St. Paul University Hospital in Dallas, Texas and lead study investigator. "Golimumab, which is an anti-TNF therapy, is a promising treatment option for multiple patient populations with this chronic and potentially debilitating inflammatory disease."

Also at week 24, patients receiving golimumab plus MT
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
(Date:8/3/2015)... Mass. , Aug. 3, 2015 Merrimack ... company will host its Second Quarter 2015 Investor Conference ... 10.    The call will cover an ... of second quarter 2015 financials. A press release detailing ... be issued the afternoon of Monday, August 10. Investors ...
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... , , , , , , , ... (Nasdaq and MTA: CTIC) announced today that the European Medicines Agency ... DLBCL which accounts for about 80% of aggressive non-Hodgkin,s lymphoma. ... for approval of pixantrone in mid-2010 and would be granted 10 ...
... DIEGO, Dec. 18 LifeVantage Corporation (OTC Bulletin ... science-based solutions to oxidative stress, announced today that the Company ... Zrii, LLC. Under the terms of this agreement, LifeVantage paid ... on the one hand, and the Company and many individuals ...
Cached Medicine Technology:European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL) 2European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL) 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/3/2015)... ... 03, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today welcomed the announcement by OPKO Health that the US Food ... new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... to announce the development of it’s new program “Designing Secure Healthcare Systems” ... architects, engineers and technology leaders from healthcare organizations with access to the tactics, ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... genetic risk factor that increases the likelihood that youth will ... of involved and supportive parenting, according to a new University ... issue of the Journal of Consulting and Clinical Psychology ... over time to see how a genetic risk factor interacts ...
... 10 Primary Wave Media, one of the ... announced the creation of its new 1-800-HOSPICE marketing ... care market has become very competitive and these ... Wave,s 1-800-HOSPICE marketing package provides individual hospices with ...
... ZweigWhite,s just-released 2009 AEC Industry Outlook: Strategy and ... shake-up in the markets that firm leaders in the ... most promising. While health care still holds the top ... on project funding, three of last year,s top five ...
... nation, , , TUESDAY, Feb. 10 (HealthDay News) -- A North Carolina ... more than doubled in that state since the early 1990s -- ... country as a whole. , "We were actually surprised by ... medicine at the University of North Carolina and the study,s lead ...
... Sport Science and Management degree programme. The first of its ... produce professionals with relevant knowledge and pertinent skills for engagement ... at facilitating the growth of the sports and leisure industry ... Asia Pacific sports market are evident. According to a global ...
... Alice Jacobs, MD, FACC, FAHA, director of the Cardiac ... is the recipient of the Drake Award. The award ... annual conference in Bethel, Maine. , The Drake ... Eugene Drake, considered to be the first physician in ...
Cached Medicine News:Health News:Study: Genetic risk for substance use can be neutralized by good parenting 2Health News:Primary Wave Media Launches 1-800-HOSPICE 2Health News:New Study Reveals Shake-Up in the Most Promising AEC Markets for 2009 2Health News:Chronic Low Back Pain Is on the Rise 2Health News:Chronic Low Back Pain Is on the Rise 3Health News:Nanyang Technological University launches first-ever sports degree in Singapore 2Health News:Nanyang Technological University launches first-ever sports degree in Singapore 3Health News:Boston Medical Center cardiologist receives Drake Award 2
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... Ultra™, the next generation of thin wall ... surgery and general soft tissue repair. For ... handling and more flexible polyproplylene mesh, you ... Ultra. Its unique Litemesh™ polypropylene microfilament construction ...
... the surrounding walls of tissue are in ... highly compliant mesh material. Less valleys and ... stabilize the implant. Atriums unique Self-Forming Plug ... gentle lateral wall force, maximizing mesh contact ...
... Atrium's pre-formed mesh onlays are pre-cut ... particular repairs that are more frequently done. ... the ProLite and ProLite Ultra and are ... laparoscopic procedures. ,Offered in both small and ...
Medicine Products: